Clinical Trial Detail

NCT ID NCT03123783
Title CD40 Agonistic Antibody APX005M in Combination With Nivolumab
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Apexigen, Inc.
Indications

lung non-small cell carcinoma

Therapies

APX005M + Nivolumab

Age Groups: senior adult

No variant requirements are available.